Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5990-5993

  Avery, Lisa M ^a,b   Steed, Molly E ^c,e   Woodruff, Ashley E ^a   Hasan, Muhammad ^b   Rybak, Michael J ^c,d  

^a ST JOHN FISHER COLLEGE   (United States)

^b ST JOSEPH S HOSPITAL HEALTH CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; CREATININE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

AGED; ARTICLE; BACKACHE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BLOOD CULTURE; BONE SCINTISCANNING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DISKITIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HUMAN; HYPOTENSION; IN VITRO STUDY; LUNG NODULE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; POST HOC ANALYSIS; PRIORITY JOURNAL; SPONDYLITIS; STAPHYLOCOCCAL BACTEREMIA; TREATMENT OUTCOME; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; WOUND;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OSTEOMYELITIS; SPINE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN;

EID: 84868014804     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01046-12     Document Type: Article

References (26)

1. Alappan R, Perazella MA, Buller GK. 1996. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann. Intern. Med. 124:316-320.
2. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmaco-kinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249.
3. Berglund F, Killander J, Pompeius R. 1975. Effect of trimethoprim- sulfamethoxazole on the renal excretion of creatinine in man. J. Urol. 114:802-808.
4. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. 2010. Daptomycin exposure and the probability of elevations in the creatine phospho-kinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50:1568-1574.
5. Burdette SD. 2009. Daptomycin for methicillin-resistant Staphylococcus aureus infections of the spine. Spine J. 9(6):e5-e8. doi:10.1016/ j.spinee.2008.11.008.
6. Clinical and Laboratory Standards Institute. 2011. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - ninth edition: approved standard M7-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Close SJ, McBurney CR, Garvin CG, Chen DC, Martin SJ. 2002. Trimethoprim-sulfamethoxazole activity and pharmacodynamics against glycopeptide-intermediate Staphylococcus aureus. Pharmacotherapy 22: 983-989.
8. Cubist Pharmaceuticals Inc. 2003. Cubicin package insert. Cubist Pharmaceuticals Inc, Lexington, MA.
9. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. 2007. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int. J. Antimicrob. Agents 30: 202-209.
10. Figueroa DA, et al. 2009. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin. Infect. Dis. 49:177-180.
11. Fridkin SK. 2001. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. 32:108-115.
12. Graber CJ, et al. 2007. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg. Infect. Dis. 13:491-493.
13. Howden BP, et al. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528.
14. Katz DE, et al. 2008. A pilot study of high-dose short duration daptomy-cin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int. J. Clin. Practice 62:1455-1464.
15. Kullar R, et al. 2011. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. Pharmacotherapy 31:527-536.
16. Lichterfeld M, Ferraro MJ, Davis BT. 2010. High-dose daptomycin for the treatment of endocarditis caused byStaphylococcus aureus with intermediate susceptibility to glycopeptides. Int. J. Antimicrob. Agents 35:96. doi:10.1016/j.ijantimicag.2009.08.019.
17. Mariani PG, Sader HS, Jones RN. 2006. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J. Antimicrob. Chemother. 58:481-483.
18. Markowitz N, Quinn EL, Saravolatz LD. 1992. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staph-ylococcus aureus infection. Ann. Intern. Med. 117:390-398.
19. Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. 2003. Trimethoprim-sulfamethoxazole revisited. Arch. Intern. Med. 163:402-410.
20. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. 2009. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann. Pharmacother. 43:1211-1219.
21. Proctor RA. 2008. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 46:584-593.
22. Steed ME, et al. 2011. Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 55:4748-4754.
23. Steed ME, Vidaillac C, Rybak MJ. 2010. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob. Agents Chemother. 54:5187-5192.
24. Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ. 2012. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob. Agents Chemother. 56:2691-2695.
25. Vidaillac C, Parra-Ruiz J, Winterfield P, Rybak MJ. 2011. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. Int. J. Antimicrob. Agents 38:301-306.
26. Yeldandi V, Strodtman R, Lentino JR. 1988. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J. Antimicrob. Chemother. 22:873-880.